Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates improved progression-free survival with lenvatinib in radioiodine-refractory thyroid cancer, indicating substantial antitumor activity despite increased adverse effects.
Key Points
- To assess the efficacy and safety of lenvatinib compared to placebo in patients with progressive radioiodine-refractory thyroid cancer.
- Randomized, double-blind, placebo-controlled trial (SELECT, NCT01321554).
- Enrolled patients with iodine-131-refractory thyroid cancer assigned to receive either oral lenvatinib or placebo.
- Lenvatinib treatment was associated with significant improvements in progression-free survival compared to placebo.
- Patients treated with lenvatinib achieved a significantly higher objective response rate than those given placebo.
- Adverse effects occurred with greater frequency among patients receiving lenvatinib than among those receiving placebo.
Cite This Study
Schlumberger et al. (2015) studied this question.